文章：

癌症中的高胰岛素血症

Hyperinsulinaemia in cancer

原文发布日期：2020-09-09

DOI: 10.1038/s41568-020-0295-5

类型: Review Article

开放获取: 否

英文摘要：

Elevated circulating insulin levels are frequently observed in the setting of obesity and early type 2 diabetes, as a result of insensitivity of metabolic tissues to the effects of insulin. Higher levels of circulating insulin have been associated with increased cancer risk and progression in epidemiology studies. Elevated circulating insulin is believed to be a major factor linking obesity, diabetes and cancer. With the development of targeted cancer therapies, insulin signalling has emerged as a mechanism of therapeutic resistance. Although metabolic tissues become insensitive to insulin in the setting of obesity, a number of mechanisms allow cancer cells to maintain their ability to respond to insulin. Significant progress has been made in the past decade in understanding the insulin receptor and its signalling pathways in cancer, and a number of lessons have been learnt from therapeutic failures. These discoveries have led to numerous clinical trials that have aimed to reduce the levels of circulating insulin and to abrogate insulin signalling in cancer cells. With the rising prevalence of obesity and diabetes worldwide, and the realization that hyperinsulinaemia may contribute to therapeutic failures, it is essential to understand how insulin and insulin receptor signalling promote cancer progression.

摘要翻译： 

循环胰岛素水平升高常见于肥胖和早期2型糖尿病患者，这是由于代谢组织对胰岛素作用不敏感所致。流行病学研究表明，较高的循环胰岛素水平与癌症风险和进展增加有关。循环胰岛素升高被认为是连接肥胖、糖尿病和癌症的主要因素。随着靶向癌症疗法的发展，胰岛素信号传导已成为治疗抵抗的一种机制。尽管在肥胖情况下代谢组织对胰岛素变得不敏感，但多种机制使得癌细胞能够保持对胰岛素反应的能力。过去十年中，在理解癌细胞中胰岛素受体及其信号通路方面取得了重大进展，并从治疗失败中汲取了许多教训。这些发现引发了大量临床试验，旨在降低循环胰岛素水平并阻断癌细胞中的胰岛素信号传导。随着全球肥胖和糖尿病患病率的上升，以及意识到高胰岛素血症可能导致治疗失败，理解胰岛素和胰岛素受体信号如何促进癌症进展变得至关重要。

原文链接：

Hyperinsulinaemia in cancer